A COVID-19 mRNA booster given during pregnancy is associated with greater transplacental antibody transfer and sustained infant antibody levels through 6 months of age.
Clinics and health plans are expanding telehealth services as increased immigration enforcement has coincided with some patients, including immigrant families, delaying or avoiding in-person medical visits.
CDC workers describe stalled HIV prevention projects, morale collapse, and heightened safety fears after budget cuts, layoffs, and a deadly shooting at agency headquarters.
KFF Health News
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A phase 3 randomized trial found that Moderna’s next-generation COVID-19 vaccine, mRNA-1283, was non-inferior to the earlier mRNA-1273 vaccine in preventing COVID-19 and produced stronger neutralizing antibody responses.
A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.